What is AYTU's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AYTU?

P/E (TTM) is n/a and 52-week range is $1.80 to $3.06 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AYTU figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AYTU?

The company profile lists revenue (TTM) near $51M, net income (TTM) near -$1.26B, EPS (TTM) near -$1.49 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aytu Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Denver, Colorado, US, 10.9M shares outstanding, ISIN US0547548588 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Aytu Biopharma Inc

$AYTU

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 75 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

Employees

Website

aytubio.com/

IPO

2017-10-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US0547548588

Headquarters

Denver, Colorado, US

Shares outstanding

10.9M

NAICS sector

Manufacturing

Institutional ownership

35.95%

Browse other companiesFree AI scores and summaries for more stocks